.
Accurate longitudinal nodule matching is a critical technical prerequisite for automated growth rate (volume doubling time) assessment in lung cancer screening. This study evaluated an artificial intelligence (AI) pulmonary nodule analysis system in all 361 UK Lung Cancer Screening (UKLS) trial participants who underwent a 3-month follow-up low-dose computed tomography (LDCT) scan. The pulmonary AI independently evaluated these baseline scans using an updated volume threshold (solid component ≥ 100 mm³ per NELSON 2.0/EUPS protocol) for cases requiring 3-month follow-up. To assess true algorithmic robustness, all AI-detected baseline candidate nodules (≥ 100 mm³) proceeded to fully automated longitudinal matching without any manual selection. The pulmonary AI identified 181 participants with 378 baseline nodules ≥ 100 mm³. In total, 39 nodules had naturally resolved at follow-up. The pulmonary AI achieved an 83.5
BACKGROUND:Hodgkin lymphoma (HL) survivors are at increased risk of late adverse events, eg, cardiovascular diseases (CVD), breast cancer (BC), hypothyroidism and severe infections. At Dutch BETER clinics, HL survivors are regularly screened for (risk factors for) these adverse events. The impact of survivorship care on the burden of disease from adverse outcomes has rarely been evaluated. METHODS:In a nationwide retrospective cohort study, we compared HL survivors invited for BETER care in 2013-2016 (intervention group) with matched survivors who were eligible for such care but were not invited until 2019-2024 (comparison group). Incidence and mortality rates for CVD, BC, hypothyroidism, and severe infections were collected from general practitioners and nationwide registries. Disability-adjusted life years (DALYs) attributable to late adverse events were compared using multivariable regression models. RESULTS:At study start, survivors in the intervention group (n = 491) and comparison group (n = 373) had a median age of 46 years; median time since HL diagnosis was 15-18 years. After 8.5 years (median), there were no significant differences in DALYs attributable to CVD, BC, hypothyroidism, and severe infections between the groups. In both groups, approximately one third of survivors acquired DALYs attributable to adverse events. Adherence to recommended screening diagnostics was high, but cardiovascular risk management and vaccination rates were suboptimal. CONCLUSION:After 8.5 years of follow-up, survivorship care for HL survivors was not associated with lower disease burden. Better care coordination, amendment of the cardiovascular risk management guidelines, and greater survivor involvement may improve long-term effectiveness of measures to prevent late adverse events.
Background and purpose:Concurrent chemoradiotherapy (cCRT) is an effective treatment for anal squamous cell carcinoma, but identifying patients with good treatment outcomes remains challenging. We aimed to develop a multivariable model combining baseline clinical and imaging (MRI, PET/CT) variables, HPV status and semi-quantitative 18F-FDG-PET/CT parameters to predict locoregional treatment failure, defined as incomplete response or local relapse, within two years after cCRT. Materials and methods:This retrospective cohort study included 152 anal cancer patients treated with cCRT between 2008 and 2023. All patients underwent pre-treatment 18F-FDG-PET/CT and ≥ 2 years of follow-up was available. Seven predictive models were constructed using combinations of (1) clinical baseline variables (age, sex, cTN-stage), (2) tumour hr-HPV status, and (3) PET/CT parameters (e.g. SUVmax, MTV42%, TLG). Model performance for predicting locoregional failure was evaluated using bias-corrected area under the receiver operating characteristic curve (AUC), using LASSO regression. Results:Locoregional failure occurred in 21 of 152 patients (14%) within two years after cCRT. The model combining hr-HPV and PET/CT parameters showed the best performance (bias-corrected AUC 0.69). In this model, hr-HPV positivity was associated with substantially lower odds of failure (OR 0.30, 95% CI 0.07-1.00), while higher MTV42% was associated with slightly increased odds (OR 1.01, 95% CI 1.00-1.05). Conclusion:The model combining hr-HPV status and semi-quantitative PET/CT parameters (particularly MTV42%) performed moderately well to predict two-year locoregional failure in anal cancer patients. These findings support further exploration of baseline risk stratification to develop models that may guide more personalised treatment strategies.
AIM:The aim of this paper is to examine inhaled formoterol concentrations in hair and assess the potential of hair analysis as a tool for measuring long-term adherence, by validation with objective data from digital inhalers. METHODS:Hair samples and digital inhaler data were collected from patients with COPD in 10 hospitals in the Netherlands as part of the TRICOLON trial. Hair samples were divided into three 1 cm segments, each representing 1 month of hair growth. Intra-patient variability was investigated. Correlations between formoterol concentrations and digitally measured inhalations were assessed. Hair colour, dyeing, sex, body mass index (BMI) and smoking status were examined for their association and effect modification. RESULTS:Of the 96 patients who provided a hair sample, 49 had sufficient quality hair sample and digital data. Low intra-patient variability was observed (intraclass correlation coefficient .94, 95% CI 0.87-0.97). Over a 3-month period, a trend was observed in the correlation between the digitally recorded inhalations and hair formoterol concentration (correlation coefficient [r] = .25, p = .087). Regarding individual segments, a significant correlation was only found in the segment closest to the scalp (r = .30, p = .039). Higher formoterol concentrations were measured in dark hair and in those with a lower BMI. No effect modification by colour, dyeing, sex, BMI or smoking was observed. CONCLUSION:Low intra-patient variability of hair formoterol concentrations was observed in patients with stable adherence. However, inter-patient variability and external factors may limit the correlation between formoterol concentrations in hair and adherence measured by a digital inhaler and thus the current utility of hair analysis as an adherence monitoring tool.